NCT06739928View on ClinicalTrials.gov

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2027

Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
DRUG

Irinotecan liposome (II) combined with adebrelimab and carboplatin

Irinotecan liposome (II) + adebrelimab + carboplatin

DRUG

etoposide combined with adebrelimab and carboplatin

etoposide + adebrelimab + carboplatin

Trial Locations (1)

510120

RECRUITING

Guangzhou Institute of Respiratory Disease (Responsible Party), Guangzhou

All Listed Sponsors
lead

Guangzhou Institute of Respiratory Disease

OTHER